Navigation Links
Columbia Laboratories Expands its Intellectual Property Portfolio Following Receipt of U.S. Patent
Date:7/17/2014

BOSTON, July 17, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry, today announced that it has expanded its intellectual property portfolio following the receipt of a patent covering bioadhesive progressive hydration tablets. The issued patent, U.S. Patent 8,765,177, pertains to a controlled, extended release delivery system for pharmaceutical compounds and can be used by the Company to develop proprietary products.

"The receipt of this patent is in keeping with our strategy of using the Company's patented delivery systems, combined with the formulation development capabilities of our wholly owned subsidiary, Molecular Profiles, to develop a portfolio of proprietary products. The patent could have a number of potential applications and increases our intellectual property portfolio pertaining to bioadhesive controlled release delivery of drugs," said Frank Condella, Columbia's president and chief executive officer.

In 2013, the Company was also granted a patent covering controlled-release pharmaceutical compositions using charged polymers, and the method of treating or preventing a disease using these new compositions. The patent, U.S. Patent 8,425,892, has a number of potential applications. It directly covers Columbia's extended release lidocaine vaginal gel (COL-1077), which had previously been developed through phase II for the treatment of pelvic pain and is currently under consideration for further development to prevent gynecological procedure related pain. There are currently no products approved for pain related to gynecological procedures.

About Columbia LaboratoriesColumbia Laboratories, Inc. provides pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry.  The Company has a successful heritage in developing pharmaceutical products, particularly in women's health.  Its most successful product to date, CRINONE® 8% (progesterone gel), is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 additional countries worldwide.  For more information, please visit www.columbialabs.com.

CRINONE® is a registered trademark of Actavis, Inc. in the U.S.

Forward Looking StatementsSafe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This communication contains forward-looking statements, which statements are indicated by the words "may," "will," "plans," "believes," "expects," "anticipates," "potential," "should," and similar expressions, which are generally not historical in nature. These include all statements relating to expected financial performance and future business or product developments.  Management believes that these forward-looking statements are reasonable as and when made.  However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management's current expectations and Columbia does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.  For a discussion of certain risks and uncertainties associated with Columbia's forward-looking statements, please review Columbia's reports filed with the SEC, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2013.Contact: Jonathan Lloyd Jones

Katja BuhrerVice President & CFO

MBS Value PartnersColumbia Laboratories, Inc.

(212) 661-7004(617) 639-1500

(646) 378-2952


'/>"/>
SOURCE Columbia Laboratories, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Cochlear Implants and BAHA Surgery at Columbia Asia Hospitals
2. What Can Healthcare Professionals Learn from Art? A Columbia University Physician Finds Answers at the Met
3. Columbia Asia Referral Hospital, Yeshwanthpur, Successfully Conducts HOLEP to Treat a 72-Year-old With Urology Disorder
4. Xenon Named Life Sciences Company of the Year by LifeSciences British Columbia
5. Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
6. Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences
7. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
8. Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation
9. New Data Support Role of Prometheus Laboratories Novel Assay in Optimizing IBD Treatment Management
10. Everett Laboratories, Inc. Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.
11. PeaceHealth Laboratories New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 Accuray Incorporated (Nasdaq: ... and TomoTherapy® Systems continue to set the bar for ... highest composite overall user satisfaction rating among radiation treatment ... 2016 MD Buyline Market Intelligence Briefing™. The most recent ... composite ratings among industry peers for 11 of the ...
(Date:1/19/2017)... RATON, Fla. , Jan. 19, 2017 /PRNewswire/ ... a medical device company specializing in the treatment ... such as keloids, with superficial radiation therapy, today ... and full year 2016 financial results on Thursday, February ... The Company will hold a conference call with ...
(Date:1/19/2017)... , Jan. 19, 2017   Science Exchange ... excited to announce that the first five replication ...  (RP:CB) have been published in eLife today. Despite ... represents the first practical evaluation of reproducibility rates ... reproducible studies. Unlike other assessments of reproducibility, the ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Tribble Insurance Agency, a family owned and ... is inaugurating a charity event to honor Chad Phillip Dermyer, a local police trooper ... Chad Phillip Dermyer and his fellow officers were conducting routine stops of suspects when ...
(Date:1/19/2017)... Madison, Mississippi (PRWEB) , ... January 19, 2017 , ... ... its Siena Center. , Siena Center is a skilled nursing facility on the grounds ... private and semiprivate rooms. It recently was voted the best nursing home in Mississippi ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Spring Create Real Impact contest from Impact Teen Drivers and California Casualty. Entries ... . , Educational grants totaling $15,000 will be awarded for the best ...
(Date:1/19/2017)... ... ... The CHP suggests that California drivers can avoid hydroplaning as well as ... the space between themselves and other vehicles, according to a January 3 article ... notes that, rain or shine, drivers should always incorporate safe driving practices in their ...
(Date:1/19/2017)... ... ... Connecticut Dermatology Group (CDG) is proud and excited to welcome back to ... Kim brings an extensive background in cutting-edge dermatology care and research to Connecticut’s largest ... Dr. Kim to the CDG team” said President and Managing Partner Dr. Steven A. ...
Breaking Medicine News(10 mins):